| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/29/2008 | US20080125418 Benzimidazole derivatives and their use as kdr kinase protein inhibitors |
| 05/29/2008 | US20080125417 4-Tert-Butyl-N-(2-methyl-3-{2-[4-(morpholine-4-carbonyl)-phenylamino]-pyrimidin-4-yl}-phenyl)-benzamide;enzyme inhibitors of Burton's tyrosine kinase (Btk); autoimmune diseases; antiinflammatory/-arthritic agents; X-linked agammaglobulinaemia; antiallergens; osteoporosis; determining the presence Btk |
| 05/29/2008 | US20080125416 Sigma Receptor Inhibitors |
| 05/29/2008 | US20080125415 Novel methods for treatment of diseases related to activated lymphocytes |
| 05/29/2008 | US20080125414 Method of Treatment |
| 05/29/2008 | US20080125413 Antagonist for calcitonin gene related peptide (Cgrp); azepinone ligands; migranes; headaches; 1-[(2-methoxyethyl)-2-oxo-6-phenylazepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide |
| 05/29/2008 | US20080125412 Containing a diazacycloalkane ring, especially a 1,4-diazepane ring, e.g., N-p-((4-(alpha-phenylmethoxycarbonylmethyl)-1,4-diazepan-1-yl)phenyl)-o-biphenylcarboxamide, for the treatment of hyperlipidemia, obesity and type II diabetes. |
| 05/29/2008 | US20080125411 Dispiro 1,2,4-trioxolane antimalarials |
| 05/29/2008 | US20080125410 7-chloro-N,N-9-trimethyl-2-(6-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indole-4-carboxamide; ethyl 7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate; 4-[(4-azetidin-1-yl)piperidin-1-ylcarbonyl]-7-chloro-9-methyl-2-phenyl-9H-pyrimido-[4,5-b]indole; Alzheimer's or Parkinson's disease |
| 05/29/2008 | US20080125409 N-tert-butyl-5-(5-methanesulfonylamino-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazole-3-carboxamide; prophylactic and/or therapeutic agent for ischemic diseases; platelet aggregation suppressant |
| 05/29/2008 | US20080125408 (5-propyl-2-oxo-1,3-dioxol-4-yl)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate for teating bacterial infections such as bronchitis, sinusitis, otitis media, brain abscess, pneumonia etc; oral bioavailability |
| 05/29/2008 | US20080125407 Method for preparation of fluticasone propionate |
| 05/29/2008 | US20080125406 Method for Treating Primary and Secondary Forms of Glaucoma |
| 05/29/2008 | US20080125405 Composition for treating or preventing olfactory disorder |
| 05/29/2008 | US20080125404 purine and pyrimidine derivatives such as Roscovitine or 2-[(1-ethyl-2-hydroxyethyl)amino]-6-benzylamine-9-isopropylpurine or olomoucine or purvalanol A for treating human systemic lupus erythematosus associated with antinuclear antibodies; methylprednisolone |
| 05/29/2008 | US20080125403 Method of Treating Men with Metabolic and Anthropometric Disorders |
| 05/29/2008 | US20080125402 Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
| 05/29/2008 | US20080125401 Use of estradiol valerate or 17beta-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido |
| 05/29/2008 | US20080125400 Use of phosphoenolpyruvate derivatives |
| 05/29/2008 | US20080125399 N-[3-(trifluoromethyl)pyridin-2-yl]-4-methyl-6-methyl-3-oxo-4-aza-5 alpha -androst-5-en-17 beta -acetamide; useful for the treatment of conditions caused by androgen deficiency such as osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, cancer cachexia, Alzheimer's disease |
| 05/29/2008 | US20080125398 oxidation of 2-{[2-(Diisopropylamino)ethyl]thio}ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidate to 2-{[2-(diisopropylamino)ethyl]sulfonyl}ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidate; salt formation, anticarcinogenic agent |
| 05/29/2008 | US20080125397 2 (SULFONYL)ETHYL N,N,N',N' tetrakis(2 chloroethyl)phosphorodia |
| 05/29/2008 | US20080125396 2-Butyl-4-{[4-(difluoromethoxy)phenyl]amino}-5-phenylisothiazole-3(2H)-thione 1,1-dioxide; cardiovascular diseases such as atherosclerosis; inflammatory and Alzheimer's diseases, lipid disorders (dyslipidemias); thionation of the isothiazol-3 (2H)-one with Lawesson's reagent |
| 05/29/2008 | US20080125395 Compositions and methods for the treatment of skin |
| 05/29/2008 | US20080125394 Continuous slow release of a oral drug containing phosphorus binder such as polyallylamine HCL, polyallylamine carbonate, lanthanum carbonate, Al/OH/3, magnesium acetate, MgCO3, CaCO3, calcium acetate, calcium citrate, calcium alginate, styrene-divinylbenzene copolymer, chitosan for hyperphosphatemia |
| 05/29/2008 | US20080125393 Methods of selectively treating diseases with specific glycosaminoglycan polymers |
| 05/29/2008 | US20080125392 Glycolipids |
| 05/29/2008 | US20080125391 administering to a mammal harboring a tumor which expresses HALRs, a Sindbis virus vector to treat the tumor, and the vector has not been modified to target a tumor-specific cellular determinant, has a preferential affinity for HALRs, a Sindbis virus E2 HALR binding domain; ganciclovir; gene therapy |
| 05/29/2008 | US20080125390 Methods for Modulating Immune and Inflammatory Responses |
| 05/29/2008 | US20080125389 Men1 is a marker and therapeutic target for breast and prostate cancer |
| 05/29/2008 | US20080125388 treating or preventing a condition of excessive cell death by administering a nucleic acid molecule encoding a protein having CPG15-2 biological activity; acts as survival factor by rescuing hippocampal and cortical neurons from cell death; inhibiting activity of CPG15-2 for cancer treatment |
| 05/29/2008 | US20080125387 Administering vector system that directs regulated erythropoietin (Epo) gene therapy in a manner that physiologically corrects the hematocrit levels in a patient in need of anemia treatment |
| 05/29/2008 | US20080125385 Decreasing activity improves beta-adrenergic response; point mutations; gene expression inhibition |
| 05/29/2008 | US20080125384 Simultaneous silencing and restoration of gene function |
| 05/29/2008 | US20080125383 For host undergoing surgery or coronary artery bypass |
| 05/29/2008 | US20080125382 Extracellular superoxide dismutase (EC-SOD) gene delivery to prevent oxidative injury |
| 05/29/2008 | US20080125381 Such as 7-(2-thienyl)-3-(2-deoxy- beta -D-ribofuranosyl)-3H-imidazo[4,5-b]pyridine; anticancer agents |
| 05/29/2008 | US20080125380 Fatty acid-anticancer conjugates and uses thereof |
| 05/29/2008 | US20080125379 Contains 3-O-beta-D-Glucopyranosyl-4-methyl-ergost-7-en-3-ol |
| 05/29/2008 | US20080125378 Use of Amygdalin Analogues for the Treatment of Psoriasis |
| 05/29/2008 | US20080125377 Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use |
| 05/29/2008 | US20080125376 Viricide against hepatitis virus; pyrrole derivatives as, for example, 3-acetyl-4,5-dimethyl-2-pyrrole carboxylic acid |
| 05/29/2008 | US20080125375 Peptide like compounds for treating coronavirus or aviviridae virus; severe acute respiratory distress syndrome |
| 05/29/2008 | US20080125364 Increasing formation of tight junctions by modulating occludin activity of transformed cells (induced by RAF1) |
| 05/29/2008 | US20080125360 Use of polypeptide YY (PYY) administered parenterally to treat pain, abdominal pain, constipation and/or diarrhea from irritable bowel syndrome, functional dyspepsia; use in combination with antidepressants or antiemetics |
| 05/29/2008 | US20080125358 Methods for Chk2 inhibitor patient selection |
| 05/29/2008 | US20080125355 Endogenous Peptide and Active Subfragments Thereof |
| 05/29/2008 | US20080125354 With triple helix and/or poly-proline type II transition state analog phosphorus based inhibitor comprising a phosphonamide, phosphinic peptide or phosphonate ester; e.g. (R,S)-2-Isopropyl-3-((1-(N-(9-Fluorenylmethoxycarbonyl)amino)-methyl)-adamantyloxyphosphinyl)propanoic acid; antitumor agents |
| 05/29/2008 | US20080125351 Forming water-in-oil emulsion from aqueous phase (water soluble polypeptide and sugar) and oil phase comprising glycolic acid-lactic acid copolymer and solvent, adding silicone oil, hardening, drying; optimizing the silicone oil to polymer ratio to improve bioavailability of peptide drug |
| 05/29/2008 | US20080124803 cDNA Corresponding to the antigenome of nonsegmented negative stranded RNA viruses and process for the production of such viruses |
| 05/29/2008 | US20080124802 Method for labeling specific cells within living cells or tissues |
| 05/29/2008 | US20080124743 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (u1) |
| 05/29/2008 | US20080124416 Therapeutic composition from goji (lycium barbarum l.), methods of making and using |
| 05/29/2008 | US20080124413 Novel composition containing extracts of butyrospermum parkii and the use of such a composition for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation hypersensitivity or pain |
| 05/29/2008 | US20080124412 Methods for reducing circulating glucose levels |
| 05/29/2008 | US20080124411 nasal strip; and an orally administered composition comprising a tissue-firming agent, a tissue-soothing agent, a tissue lubricant, and an expectorant; for combating snoring |
| 05/29/2008 | US20080124408 includes an alkylamide fraction comprising a 2-ene alkylamide fraction and a 2,4-diene alkylamide fraction; for the prevention and treatment of colds and flu |
| 05/29/2008 | US20080124407 Inhibiting cyp3a4 induction |
| 05/29/2008 | US20080124404 reducing at least one of total cholesterol, LDL-cholesterol, free fatty acids, or triglycerides; composition comprising berberine or a pharmaceutically acceptable salt thereof and a multi-drug resistant pump (MDR) inhibitor |
| 05/29/2008 | US20080124402 N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators |
| 05/29/2008 | US20080124401 Method of treating endothelial injury |
| 05/29/2008 | US20080124400 Microparticles With High Loadings Of A Bioactive Agent |
| 05/29/2008 | US20080124399 Such as capsules/beads of cyclobenzaprine hydrochloride |
| 05/29/2008 | US20080124398 Modified release dosage forms of skeletal muscle relaxants |
| 05/29/2008 | US20080124396 polymer synthesized by a cross-coupling reaction of polymer scaffold units and xenoantigens |
| 05/29/2008 | US20080124393 Time-release agent containing poorly soluble agent such as clozapine; release the agent following administration for a time period ranging from about 2 to about 24 hours or longer |
| 05/29/2008 | US20080124389 Nanoparticulate and Controlled Release Compositions Comprising Cyclosporine |
| 05/29/2008 | US20080124388 tannins obtained through total or semi-chemical syntheses; can sufficiently promote early growth of new blood vessels in the infarct zone to quickly restore the coronary blood circulation once an ischemic event occurs |
| 05/29/2008 | US20080124387 Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients |
| 05/29/2008 | US20080124386 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 05/29/2008 | US20080124385 Methods for Transmembrane Treatment and Prevention of Otitis Media |
| 05/29/2008 | US20080124384 Heteroaryl Substituted Piperazinyl-Pyridine Analogues |
| 05/29/2008 | US20080124381 sufficient film strength and rapid disintegration profiles; high and low molecular weight water soluble polymer, an active agent, hydroxypropyl methylcellulose, hydroxypropyl cellulose |
| 05/29/2008 | US20080124379 Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
| 05/29/2008 | US20080124377 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 05/29/2008 | US20080124376 Ocular devices and methods of making and using thereof |
| 05/29/2008 | US20080124375 Device and Methods of Sequential, Regional Delivery of Multiple Cyctotoxic Agents and Directed Assembly of Wound Repair Tissues |
| 05/29/2008 | US20080124374 Decellularized bone marrow extracellular matrix |
| 05/29/2008 | US20080124372 Morphology profiles for control of agent release rates from polymer matrices |
| 05/29/2008 | US20080124367 50% by mass to 95% by mass of an oil constituent, which contains 10% by mass to 100% by mass of a solid or semisolid oil constituent, and 5% by mass to 50% by mass of particles; enhancing percutaneous absorption of a water-soluble agent |
| 05/29/2008 | US20080124366 Methods and Compositions for Treating Tumors |
| 05/29/2008 | US20080124365 Using single-stranded DNA template to generate antisense RNA sequences for treatment and prevention of viral infection and cell proliferative disorders; viricides; antitumor agents |
| 05/29/2008 | US20080124354 Her-2 protein fragments, recombinant peptides comprising same, nucleotide molecules encoding same, recombinant vaccine vectors and immunogenic compositions comprising same, and methods for inducing immune response and treating cancer, comprising same |
| 05/29/2008 | US20080124352 Methods to bypass CD4+ cells in the induction of an immune response |
| 05/29/2008 | US20080124349 Method or Use of a Solubilized Glucan Product to Increase Immunostimulation in Animals |
| 05/29/2008 | US20080124346 Chimeric metal binding protein for use in prevention and treatment of cancer, diabetes, cardiovascular disease, obesity, metabolic disease, neurodegenerative disease, gastrointestinal disease, autoimmune disease, rheumatological disease and infectious disease. |
| 05/29/2008 | US20080124339 Monoclonal antibody specific to mucosal addressin cell adhesion molecule (MAdCAM) for use in prevention and treatment of inflammatory, gastrointestinal, liver disorders |
| 05/29/2008 | US20080124338 Using mixture comprising immunoglobulin and terminal region of nuclear factor kappa beta as therapeutic tool in treatment of sexually transmitted, ocular, cancer and atherosclerotic disorders |
| 05/29/2008 | US20080124335 Novel Polypeptide and the Use Thereof |
| 05/29/2008 | US20080124333 Administering glutamate release inhibitor and glutamate receptor antagonist; antiapoptosis |
| 05/29/2008 | US20080124331 Compositions and methods for the diagnosis and treatment of tumor |
| 05/29/2008 | US20080124329 Conditioned Cell Immunization |
| 05/29/2008 | US20080124323 Using fructooligosaccharides as components of probiotics for use in prevention and treatment of infection |
| 05/29/2008 | US20080124322 Activation and inhibition of the immune system |
| 05/29/2008 | US20080124317 Diagnos and Treatment of Fibrosis Related Pathology |
| 05/29/2008 | US20080124312 Using topical skin treatment to combat age-related skin pigmentation, skin elasticity, color and smoothness disorders |
| 05/29/2008 | US20080124309 Cell Surface Glycoprotein |
| 05/29/2008 | US20080124306 Vigor Enhancement Via Administration of Pyrimidine Derivatives |
| 05/29/2008 | US20080124303 Exhibits tubercin activity; immune enhancers such as glycyrrhizin (GR), glycyrrhetic acid, and Chinese herbal extracts |
| 05/29/2008 | US20080124301 Oligonucleotide for use in prevention and treatment of cell proliferative and nervous system disorders; antisense agents |